| Literature DB >> 30101095 |
Colin F Mitchell1, Lee Ann Fugler1, Susan C Eades1.
Abstract
Laminitis is an extremely painful condition resulting in damage to the soft tissues anchoring the third phalanx to the hoof, which can result in life-threatening debilitation. Specific therapy is not available. The most important principles of therapy include aggressive nutritional and medical management of primary disease processes, cryotherapy, anti-inflammatory therapy, pain management, and biomechanical support. This review focuses on the principles of evidenced-based therapies.Entities:
Keywords: laminitis biomechanics; laminitis pain; laminitis treatment
Year: 2014 PMID: 30101095 PMCID: PMC6067769 DOI: 10.2147/VMRR.S39967
Source DB: PubMed Journal: Vet Med (Auckl) ISSN: 2230-2034
Principles of acute laminitis therapy
| 1. Nutritional and medical management of the primary disease process |
| 2. Cryotherapy achieving temperatures below 10°C continuously for at least 48 hours |
| 3. Anti-inflammatory therapy for sepsis-related acute laminitis |
| 4. Pain control |
| 5. Biomechanical optimization |
Medications often used in equine acute laminitis
| Medication | Dosage |
|---|---|
| Cyclooxygenase inhibitors | |
| Phenylbutazone | 2.2–4.4 mg/kg IV or PO every 12 hours |
| Flunixin meglumine | 0.5 –1.1 mg/kg IV or PO every 12 hours |
| Firocoxib | 0.1 mg/kg PO every 24 hours |
| Other anti-inflammatory drugs | |
| Dimethyl sulfoxide | 0.1–1.0 g/kg diluted to 10% solution IV every 8–24 hours |
| Pentoxifylline | 8.5–10 mg/kg IV or PO every 12 hours |
| Pain control (supplements to cyclooxygenase inhibitors) | |
| Lidocaine | 1.3 mg/kg IV bolus, followed by 3.0 mg/kg/hour continuous rate infusion IV |
| Butorphanol | 0.01–0.05 mg/kg three to six times daily IV, or 0.04–0.1 mg/kg three to six times daily intramuscularly |
| Combination continuous rate infusion | |
| Lidocaine | 1.3 mg/kg IV bolus, followed by 3.0 mg/kg/hour |
| Ketamine | 0.4–1.2 mg/kg/hour |
| Butorphanol | 18 μg/kg body weight, then 10–23 μg/kg body weight/hour |
| Neuropathic pain modulation | |
| Gabapentin | 20 mg/kg PO every 12 hours |
Abbreviations: IV, intravenously; PO, orally.
Figure 1Material on the hoof.
Notes: Once the impression material is mixed together, it is applied over the frog and collateral sulci. The material is pushed into place but does not extend to the apex of the frog. Slightly more material than is needed is applied and left bulging over the central sulcus of the frog. The foot is then placed on the ground and the contralateral limb is elevated briefly, which will extrude excess material caudally, behind the heel bulbs.
Figure 2Material on ground.
Notes: The material has cured and is now firm. It will retain its shape; therefore, trimming of the material to fit the foot or unload specific areas can be performed without losing a secure fit.